The New England journal of medicine, 2023-02, Vol.388 (5), p.395-405
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
- Ist Teil von
- The New England journal of medicine, 2023-02, Vol.388 (5), p.395-405
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In patients with treatment-resistant hypertension and blood pressure of 130/80 mm Hg or higher, the aldosterone synthase inhibitor baxdrostat reduced blood pressure in a dose-related manner.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2213169Titel-ID: cdi_proquest_miscellaneous_2733200490
- Format
- –
- Schlagworte
- Aldosterone, Aldosterone - blood, Aldosterone - metabolism, Aldosterone synthase, Antihypertensive Agents - adverse effects, Antihypertensive Agents - therapeutic use, Antihypertensives, Blood pressure, Blood Pressure - drug effects, Cardiology, Clinical Medicine, Clinical Medicine General, Cortisol, Cytochrome P-450 CYP11B2 - antagonists & inhibitors, Diabetes, Diuretics, Double-Blind Method, Endocrinology, Endocrinology General, Enrollments, Humans, Hypertension, Hypertension - drug therapy, Hypertension - etiology, Lipids, Nephrology, Nephrology General, Patients, Placebos, Potassium, Prevention, Regression analysis